Qiagen N.V. (QGEN) exhibits 62.2% gross margins and 8.0% return on invested capital within Health Care (Biotechnology: Biological Products (No Diagnostic Substances)), balanced against a 17.6x enterprise multiple and 4.8% implied options volatility.
Sustained 62.2% gross profitability converts into 22.3% operating margin and 8.0% ROIC, outpacing sector cost of capital.
ROIC: 8.0% // GM: 62.2%YoY revenue trajectory of +5.7% paired with 4.37% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +5.7% // FCF YLD: 4.37%Altman Z-Score of 3.54 and Piotroski F-Score of 9/9 indicate low near-term refinancing stress.
ALTMAN Z: 3.54 // F-SCORE: 9/9Trading at 24.4x trailing P/E (22.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 24.4x // EV/EBITDA: 17.6xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $50.22 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Biological Products (No Diagnostic Substances) require continuous execution to defend 20.3% net margins.
NET MARGIN: 20.3% // D/E: 0.44x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for QGEN & activate live FRED threshold breach alerts.